Cancer Genetics (NASDAQ: CGIX) is a diagnostics company developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. Its proprietary tests target cancers where prognosis information is critical and where predicting treatment outcomes using currently available techniques is limited. The company has commercially launched its first proprietary microarray diagnostic tests, and plans to provide the tests and services to oncologists and pathologists, cancer centers and physician offices, and to biopharmaceutical companies and clinical research organizations. For more information, visit the company’s website at www.cancergenetics.com